A database of publications about African genetic resources and digital sequence information — real bibliographic metadata pulled from PubMed, with a durable link back to the source record. Papers that aren't on PubMed, given by curators as evidence, are listed beside them from Crossref, linked by their DOI to the publisher. Full text is frequently paywalled even when the abstract/metadata is open, so this is a metadata catalog with an outbound link, not a hosted archive; this platform never claims to host or redistribute full text.
Mechanistic Profiling of Phenethyl Isothiocyanate in CCRF-CEM Acute Lymphoblastic Leukemia Cells.
Prajapati S, Lei X, Elbadawi M, Dawood M, Klauck SM, Gong W, Shan L, Kampeis P, Efferth T, Lu X · Pharmaceuticals (Basel) (2026)
Sudan · DOI: 10.3390/ph19101631
Background/Objectives: Phenethyl isothiocyanate (PEITC), a bioactive compound found in cruciferous vegetables, exhibits potent anti-cancer activity, but its molecular mechanisms in acute lymphoblastic leukemia (ALL) remain poorly defined. This study aimed to investigate the anti-leukemic effects of PEITC. Methods: PEITC cytotoxicity was assessed in human cancer cell lines using resazurin reduction assays. Microarray and Ingenuity Pathway Analysis (IPA) were used to investigate altered molecular signaling pathways. Functional assays were performed to assess DNA damage, cell-cycle progression, apoptosis, autophagy, mitochondrial membrane potential, microtubule organization and endothelial tube formation. Western blotting was performed to examine pathway-related proteins, and preliminary in vivo antitumor activity was evaluated using a CCRF-CEM zebrafish xenograft model. Results: PEITC exerted potent cytotoxicity against CCRF-CEM cells (IC50 = 1.76 ± 0.07 µM). Microarray and IPA analyses predicted inhibition of PI3K/AKT/mTOR signaling, which was further supported by Western blot analysis. Functional assays demonstrated that PEITC induced DNA damage, cell cycle perturbation, mitochondrial dysfunction, and apoptotic and autophagic responses. PEITC also disrupted microtubule organization in GFP-tagged α-tubulin-expressing U2OS cells. Furthermore, PEITC suppressed endothelial tube formation in EA.hy926 cell lines and exhibited preliminary in vivo antitumor activity in a zebrafish xenograft model (n = 10). Conclusions: These findings provide mechanistic insights into the anti-leukemic activity of PEITC and demonstrate its effects on multiple cellular processes associated with leukemia cell survival and proliferation, supporting further investigation of its therapeutic potential in ALL.
Early insights into predicted efficacy of Ebola monoclonal antibodies for the 2026 Bundibugyo virus disease outbreak.
Nabukeera KC, Luakanda-Ndelemo G, Semawule S, Ayitewala A, Adroba-Tandele P, Walakira A, Amuri-Aziza A, Jansen D, Galiwango R, Kinganda-Lusamaki E, Tebba A, Ngandu C, Ssemaganda A, Tshiani-Mbaya O, Kanyerezi S, Kyokushaba J, Akil-Bandali P, Makoha C, Oundo HR, Kimbonza S, Balinandi S, Mukadi-Bamuleka D, Nakintu V, Nsio J, Mugerwa I, Kadobera D, Euriene D, Mulangu S, Ayouba A, Eliu M, Gidudu S, Kyobe Bosa H, Wayengera M, Rimoin AW, Lubwama B, Kagirita A, Ahuka-Mundeke S, Mwamba D, Kambugu A, Kaleebu P, Happi C, Liesenborghs L, Carroll MW, Maes P, Nachega JB, Peeters M, Akilimali P, Bahatungire R, Muruta A, Kindrachuk J, Rambaut A, Kyabayinze D, Olaro C, Vercauteren K, Muyembe-Tamfum JJ, Nabadda S, Atwine D, Jjingo D, Wawina-Bokalanga T, Mbala-Kingebeni P, Ssewanyana I · Nat Commun (2026)
Uganda · DOI: 10.1038/s41467-026-78077-9
The 2026 Bundibugyo virus disease (BVD) outbreak in the DRC and Uganda raises urgent questions about the efficacy of existing Ebola virus (EBOV) monoclonal antibodies (mAbs) against Bundibugyo virus (BDBV). Here, we perform genomic and structural analyses of 44 BDBV sequences, including 12 from the 2026 outbreak, to assess mAb binding to the viral glycoprotein (GP). While the MBP134 cocktail epitopes remain conserved, mAb114 (Ebanga) binding is compromised by E112D and P116A mutations, causing off-target binding and reduced affinity. Structural modeling of Inmazeb shows that while Odesivimab maintains epitope binding, Atoltivimab and Maftivimab fail to bind their designated sites individually, though the complete trimeric cocktail demonstrates BDBV synergistic binding. These computational models predict mAb114 efficacy against BDBV may be compromised due to epitope mutations affecting binding affinity, whereas MBP134 retains conserved targeting and holds promise as a broadly protective therapeutic. The complex binding behavior of Inmazeb components points to the importance of antibody combinatorial effects for treatment efficacy. These observations warrant urgent experimental validation through neutralization assays.
Genetic Variability of IFNAR2 Gene and Risk of COVID-19 Critical Illness Among the Tunisian Population.
Azri A, Althumairy DA, Memni H, Almalki MA, Hadj Hassine I, Chatti N, Gharbi J, Ben M'hadheb M · Viruses (2026)
Tunisia · DOI: 10.3390/v18101149
The IFNAR2 gene encodes an essential component of the type I interferon receptor, which is essential for antiviral defense. It has been proven that the severity of COVID-19 may be influenced by the genetic variants in IFNAR2; however, the results are inconclusive in the African cohorts. Thus, in this study, we investigate the association between three IFNAR2 SNPs and the critical form of COVID-19 in the Tunisian population. A total of 413 COVID-19 patients classified as hospitalized with critical illness (ICU) (n = 46) and non-hospitalized (n = 367) are included. Genotyping of three IFNAR2 polymorphisms (rs1051393, rs2236757, rs9984273) was performed using Taq Man RT-PCR assays. rs2236757 (OR = 0.31, 95% CI: 0.16-0.60), p = 4 × 10-4) and rs9984273 (OR = 0.41, 95% CI: 0.22-0.76, p = 0.0055) were associated with COVID-19 severity with a potential protective effect. However, rs1051393 did not show a significant association with disease severity. Additionally, exploratory haplotype analysis suggested a possible protective association for the TAC haplotype (OR = 0.11, 95% CI: 0.02-0.86, p = 0.036), based on a very small number of carriers and not significant after correction for multiple testing. The GAC haplotype, absent from ICU patients, yielded a continuity-corrected OR of 0.03 (95% CI [0.002-0.53]); this estimate rests on a zero cell and is hypothesis-generating only. These preliminary findings, obtained from a single-center cohort with a limited number of critically ill patients, warrant replication in larger, independent, and multicentric populations.
Emerging henipaviruses and future pandemic preparedness: diagnostic delays, zoonotic spillover, and One Health challenges.
Zitouni A · Front Public Health (2026)
Algeria · DOI: 10.3389/fpubh.2026.1875406
Henipaviruses are among the most concerning emerging zoonotic pathogens because of their high mortality rates, neurological involvement, broad host range, and outbreak potential. This mini review discusses diagnostic limitations, outbreak amplification, zoonotic spillover, surveillance fragmentation, and future pandemic preparedness strategies associated with Nipah, Hendra, and Langya henipaviruses. Unlike previous reviews mainly focused on descriptive virology and epidemiology, this review emphasizes diagnostic preparedness, surveillance weaknesses, outbreak amplification mechanisms, and future One Health response strategies. Current evidence suggests that delayed diagnosis, fragmented surveillance systems, environmental disruption, and limited rapid diagnostic capacities continue to increase future spillover risks. Strengthening One Health preparedness frameworks, rapid diagnostics, genomic surveillance, and international collaboration remains essential for reducing future pandemic threats.
Shared Genetics of Hypertension and Preeclampsia Converges on Immune Regulation.
Farahat MA, Abbas M, Melese M, Gaye A · Hypertension (2026)
Egypt · DOI: 10.1161/HYPERTENSIONAHA.126.27327
Hypertension and preeclampsia are clinically distinct, yet biologically related conditions characterized by vascular dysfunction and elevated cardiovascular risk. Although genome-wide association studies have identified loci associated with blood pressure traits and preeclampsia, the functional mechanisms linking shared variants to gene regulation and clinical phenotypes remain unclear.
We integrated genome-wide association study summary statistics for hypertension, systolic blood pressure, diastolic blood pressure, and preeclampsia to identify shared variants (P≤1×10-4). Cis-expression quantitative trait loci analyses were performed in whole blood using RNA sequencing data from 180 Black women. Significant associations (false discovery rate ≤0.05) were evaluated for replication across vascular, metabolic, and endocrine tissues in the Genotype-Tissue Expression project. Associations between gene expression and blood pressure traits were also assessed.
We identified 4792 shared genome-wide association study variants, of which 4663 were tested in expression quantitative trait loci analyses, yielding 1837 significant variant-gene associations across 78 genes. Replication in the Genotype-Tissue Expression project confirmed 645 associations involving 24 genes, many showing cross-tissue regulatory effects. Three genes (C4B, HLA-C, and HLA-DQB1) demonstrated convergent evidence across genome-wide association study, gene regulation, and expression-trait analyses. C4B expression was positively associated with hypertension and systolic blood pressure, while HLA-C showed negative associations with hypertension, systolic blood pressure, and diastolic blood pressure. HLA-DQB1 expression was specifically associated with diastolic blood pressure, suggesting trait-specific effects.
These findings highlight immune-related pathways as key mediators linking hypertension and preeclampsia. Integrating genetic, transcriptomic, and phenotypic data provides a framework for identifying functionally relevant loci and advancing mechanistic insights into cardiometabolic and pregnancy-related disorders.
Clinical outcomes and prognostic factors in pediatric acute myeloid leukemia with monocytic differentiation: a single-center cohort study from Egypt.
Ahmed TAA, Hammad M, Soliman S, Elsharkawy N, Salem SI, Ahmed S, Elhaddad A · Front Oncol (2026)
Egypt · DOI: 10.3389/fonc.2026.1969723
Acute myeloid leukemia (AML) with monocytic differentiation (FAB M4/M5 subtypes) is a distinct subtype of pediatric AML characterized by aggressive clinical behavior and common extramedullary involvement. Despite therapeutic advances, outcomes remain suboptimal, particularly in resource-limited settings. The study aimed to evaluate the clinical characteristics, treatment outcomes, and prognostic markers in pediatric patients with AML, FAB M4/M5 subtypes.
A retrospective cohort study analyzing 193 patients with AML, FAB M4/M5 subtypes diagnosed at the Children's Cancer Hospital, Egypt-57357 (CCHE-57357) between January 2016 and December 2021.
The cohort comprised 131 patients with M4 and 62 with M5 morphology. Median follow-up was 62.0 months among survivors and 37.6 months for the entire cohort. Three- and five-year OS were 53.1% and 48.3%; three- and five-year EFS were 48.2% and 45.5%. Five-year CIR was 23.8%. Forty-eight patients (24.9%) died during induction. Multivariate Cox regression identified MRD positivity after first induction (HR 2.868, 95% CI 1.133-7.260, p = 0.026) and monosomy 7 (HR 6.206, 95% CI 2.692-14.306, p < 0.001) as independent adverse prognostic factors. Conversely, inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB::MYH11 was an independent favorable prognostic factor (HR 0.253, 95% CI 0.108-0.592, p = 0.002). 14 high-risk pediatric AML patients underwent HSCT post-induction; three experienced adverse outcomes, comprising relapses (n = 2), and acute GVHD (n = 1).
Genetic findings and treatment response were associated with outcome, supporting a complete diagnostic assessment. Improving survival requires precise risk stratification, MRD-guided therapy, and robust supportive care.
The chromosome-level annotated reference genome MakAnk1.0 reveals a putative signature of selection for long horns and provides insights into the demographic history of Ankole cattle.
Long-horned Ankole cattle belong to the Sanga group of cattle, which is widely distributed throughout sub-Saharan Africa. They are valued for disease, vector, and parasite tolerance, adaptation to harsh tropical environments, in addition to their unique cultural significance. In this study, a haplotype-aware, chromosome-resolved genome of Ankole cattle (MakAnk1.0) spanning 2.84 Gb, with a scaffold N50 of 110.9 Mb was assembled from PacBio HiFi and Omni-C data. The primary assembly attained 99.5% BUSCO completeness, while haplotypes 1 and 2 had lengths of 2.69 and 2.62 Gb, scaffold N50 of 106.41 and 106.48 Mb, and BUSCO scores of 98.9% and 96.7%, respectively. Gene prediction for the primary assembly yielded 19,406 genes, with a BUSCO completeness score of 88.7%. Repeat sequences accounted for 56.41% of the primary assembly, whereas haplotypes 1 and 2 contained 54.71% and 54.86%, respectively. Using the assembled genome, 27.5 million SNPs and 3.6 million INDELs were discovered, while genome-wide RAiSD analysis identified 421 candidate genomic regions under selection, from which 256 genes were subsequently annotated. These included the HLCS gene, which plays a role in biotinylation and keratinization, potentially supporting development of the long horns in Ankole cattle. Moreover, the annotated genes under selection overlapped with economically significant QTLs in tropical cattle, including tick resistance. Furthermore, the estimated recent effective population size (Ne) trajectory revealed a population contraction, with contemporary Ne estimates ranging from 228 to 278. Collectively, this study provides a valuable genomic resource for advancing research, breed improvement, and conservation of the transboundary Ankole cattle.
Antimicrobial Resistance in E. coli and Salmonella spp. Across Romanian Animal-Food-Environment Interfaces: Current Evidence and One Health Knowledge Gaps.
Bucur IM, Moza AC, Ivan AA, Moldovan ID, Udrea AV, Grigoreanu AA, Ban-Cucerzan A, Amin I, Tirziu E · Microorganisms (2026)
Egypt · DOI: 10.3390/microorganisms14102144
Antimicrobial resistance (AMR) is an important One Health challenge, yet evidence on resistant Escherichia coli and Salmonella spp. in Romania is dispersed across animal species, food matrices, environmental compartments, and surveillance systems. This comprehensive narrative review synthesizes and critically evaluates evidence across animal-food-environment interfaces and places it in the context of broader European AMR patterns. Particular attention is given to isolate origin, resistance phenotypes, multidrug resistance, major resistance determinants, molecular epidemiology, and the strength of evidence supporting cross-sector connections. Studies most frequently addressed poultry and swine, where resistance to ampicillin, fluoroquinolones, sulfonamides, and tetracyclines was repeatedly reported, together with extended-spectrum cephalosporin resistance, particularly in E. coli. Evidence from cattle, foods of animal origin, companion animals, wildlife, wastewater, and aquatic environments shows that resistant bacteria and antimicrobial resistance genes occur across multiple compartments. Substantial heterogeneity in sampling design, susceptibility testing, and molecular characterization limits direct comparison between studies, while epidemiologically linked investigations and whole-genome sequencing across connected reservoirs remain uncommon. Priorities include more standardized cross-sector surveillance, stronger environmental monitoring, expanded genomic epidemiology, improved data interoperability, and continued antimicrobial stewardship. By integrating fragmented national evidence, this review identifies both well-characterized sectors and interfaces where important evidence gaps remain.
Oleaginous fungi offer a sustainable alternative to plant-based feedstocks for biodiesel production, yet their industrial potential remains limited due to high processing costs and strain-dependent performance. Here, we report that the endophytic fungus Fusarium solani 102F, isolated from a drought-tolerant legume tree in a hot-arid region, accumulates lipids and serves as a promising microbial platform for biodiesel production. Through systematic screening of nine endophytic isolates, F. solani 102F emerged as the top lipid producer with low biomass accumulation. Stepwise preliminary screening of culture conditions, including incubation time, agitation, pH, temperature, carbon and nitrogen sources, and salt, significantly increased biomass and lipid production. The highest FAME was achieved with glucose and casein as the best carbon and nitrogen sources, respectively, at 25 °C, pH 5.0, and 200 rpm shaking over seven days. Moderate salt level further boosted lipid accumulation compared with high salt level. Direct transesterification of F. solani 102F biomass yielded 15.8% FAMEs, supporting its potential as a microbial feedstock for biodiesel production. Importantly, we demonstrate that waste eggshell-derived CaO acts as a low-cost, effective heterogeneous biocatalyst for the transesterification of extracted fungal lipids from F. solani 102F, increasing biodiesel yield from 15.8% in the non-eggshell treatment to 27.02%, corresponding to a 71% relative increase. The fatty acid methyl esters resulting from transesterification with ES-derived CaO were analyzed by GC-MS, revealing a transesterified lipid profile enriched in C16-C18 monounsaturated chains, making them highly suitable for biodiesel production. This integrated approach, combining a robust fungal strain with waste eggshell-derived catalyst, provides a potential route for microbial biodiesel production, advancing circular bioeconomy strategies for renewable energy.
Ebola Virus Persistence in Immune-Privileged Niches: Molecular Mechanisms, Host-Virus Interactions, and Therapeutic Opportunities.
Alanazi A, Albalawi WO, Alshammari ES, Alenezi MA, Shahin HEA, Ibrahim MN · Microorganisms (2026)
Egypt · DOI: 10.3390/microorganisms14102312
Ebola virus disease (EVD) has traditionally been conceptualized as an acute, fulminant illness culminating in either death or apparent systemic viral clearance. However, clinical, virological, and genomic evidence gathered since the 2013-2016 West African epidemic demonstrates that Ebola virus (EBOV) can persist for months to years within immunologically privileged anatomical compartments, particularly the central nervous system, eye, and male reproductive tract, after blood viremia becomes undetectable. Importantly, the strength of evidence differs by endpoint: RT-PCR positivity demonstrates persistence of viral RNA, recovery in culture demonstrates replication-competent virus, and documented transmission requires epidemiological and, where available, genomic linkage. Persistent infection has been associated with clinically important outcomes, including relapsing meningoencephalitis, genomically supported sexual transmission long after recovery, and outbreak resurgence linked to persistent human viral lineages. Synthesizing evidence across human cohort studies, case reports, non-human primate models, and organoid systems, this review examines the anatomical, molecular, and immunological factors that may permit EBOV survival in privileged niches. Structural barriers and local immunoregulatory environments are established features of these compartments, whereas the contributions of defective viral genomes, cell-type-specific interferon responses, exosome- or cell-mediated spread, host immunogenetic variation, and acute-phase treatment to long-term reservoir establishment remain supported to differing degrees and, in several cases, are still mechanistic hypotheses. Although monoclonal antibodies and direct-acting antivirals have transformed acute-phase outcomes, their effects on established tissue reservoirs remain incompletely defined. key knowledge gaps establishing the relationship between viral RNA detection and true infectivity, defining correlates of protection against relapse, and determining how acute-phase therapeutic choice influences reservoir establishment remains essential for developing compartment-penetrant treatments, updating survivor care guidelines, and preventing future outbreak resurgences.